We connected with Reason (the person) to get the inside track on hot areas for Longevity R&D.
Longevity.Technology: Advocacy runs through Reason like a...
Hype or hyper-exciting? Kate Batz of Longevity.Capital shares her views on the Longevity landscape and its investment potential: pragmatic optimism, but full of opportunity.
In the...
Talking venture capital and the Longevity investment landscape with Elysium Health CEO Eric Marcotulli.
While we believe it's clear the investment opportunity in Longevity is...
Virtuleap currently fundraising to build headcount and capitalise on cognitive illness detection algorithms.
Ever since the US Federal Trade Commission fined Lumosity $2 million for...
Forward Partners’ Luke Smith shares his views on early stage investment.
With the inaugural Biohacking Congress arriving in London tomorrow, we had just enough time...
Talking investment with Octopus Ventures’ Uzma Choudry and what she's looking for in a breakthrough technology.
Next week, the first Biohacking Congress will be held...
Aging2.0 announces inaugural VOLTAGE event, connecting entrepreneurs and innovators to build a single market for active and healthy aging in Europe.
This April, Aging2.0 will...
AgeMeter brings physical age measurement into the 21st century.
With the recent explosion in direct-to-consumer genetic testing kits and services, the measurement of our functional...
New open-access analytical report profiles top technologies, sectors, trends, companies, investors, R&D hubs and influencers in the Global NeuroTech Industry
“Global NeuroTech Industry Landscape Overview...
Alkahest announced today that they have initiated a phase 2 clinical trial with funding from the Michael J. Fox Foundation (MJFF).
Today's press release reveals...
A new partnership between Legal & General and Edinburgh University aims to address the societal and economic implications of an aging society.
The world is...
Singapore thrives on its prime location at the crossroads of Asia's biggest markets, low business tax and great IT infrastructure; it is well-positioned to...
Top Yale lab spawns new company focused on development of glucosepane-cleaving drugs.
San Francisco based biotech start-up Revel Pharmaceuticals has announced itself to the...
Major new prize announced to help identify how cells intentionally self-organise and communicate; George Church part of judging panel.
The origin of life is often...
Going public as a Longevity stock is all about good timing and good clinical results: Some stand-out performers have experienced a volatile year.
The world’s...
Acquisition of Human Longevity’s oncology division for $37m demonstrates both the opportunities and challenges for Longevity investing.
On Friday, NeoGenomics announced that it had agreed...
Coming around again – Italian team hopes to use repeated nucleobases to delay aging through extending telomeres.
Inflammation is a double-edged sword; while it is necessary...
We speak with GRG's Johnny Adams, a key contributor to the Longevity2020 online conference, about his quest for more healthy years.
One of the speakers at this month’s...
We speak with a key contributor to the Longevity2020 online conference about biological aging.
UK start-up AgeCurve is focused on the measurement of aging and...
